

APD926Hu01 100µg Active Tumor Necrosis Factor Receptor Superfamily, Member 14 (TNFRSF14) Organism Species: Homo sapiens (Human) *Instruction manual*

FOR IN VITRO USE AND RESEARCH USE ONLY NOT FOR USE IN CLINICAL DIAGNOSTIC PROCEDURES

1th Edition (Apr, 2016)

[PROPERTIES]

Source: Prokaryotic expression.

Host: E. coli

Residues: Ser41~Ser209

Tags: N-terminal His-tag

Purity: >95%

Buffer Formulation: 20mM Tris, 150mM NaCl, pH8.0, containing 0.05% sarcosyl and 5% trehalose.

Applications: Cell culture; Activity Assays.

(May be suitable for use in other assays to be determined by the end user.)

Predicted isoelectric point: 6.8

Predicted Molecular Mass: 21.6kDa

Accurate Molecular Mass: 22kDa as determined by SDS-PAGE reducing conditions.

[<u>USAGE</u>]

Reconstitute in 20mM Tris, 150mM NaCl (pH8.0) to a concentration of 0.1-1.0 mg/mL. Do not vortex.

[STORAGE AND STABILITY]

Storage: Avoid repeated freeze/thaw cycles.

Store at 2-8°C for one month.

Aliquot and store at -80°C for 12 months.

Coud-Clone Corp.

Stability Test: The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37°C for 48h, and no obvious degradation and precipitation were observed. The loss rate is less than 5% within the expiration date under appropriate storage condition.

[<u>SEQUENCE</u>]

SCKEDEYPVG SECCPKCSPG YRVKEACGEL TGTVCEPCPP GTYIAHLNGL SKCLQCQMCD PAMGLRASRN CSRTENAVCG CSPGHFCIVQ DGDHCAACRA YATSSPGQRV QKGGTESQDT LCQNCPPGTF SPNGTLEECQ HQTKCSWLVT KAGAGTSSSH WVWWFLSGS

[ACTIVITY]

TNFRSF14 (Tumor necrosis factor receptor superfamily member 14) belongs to the tumor necrosis factor receptor superfamily. TNFRSF14 functions in signal transduction pathways that activate inflammatory and inhibitory T-cell immune response. It binds herpes simplex virus (HSV) viral envelope glycoprotein D (gD), mediating its entry into cells. A binding ELISA assay was conducted to detect the association of TNFRSF14 with TNFa. Briefly, TNFRSF14 were diluted serially in PBS, with 0.01%BSA (pH 7.4). Duplicate samples of 100uL TNFRSF14 were then transferred to TNFa-coated microtiter wells and incubated for 2h at 37°C. Wells were washed with PBST and incubated for 1h with anti-TNFRSF14 pAb, then aspirated and washed 3 times. After incubation with HRP labelled secondary antibody, wells were incubated 15-25 minutes at 37°C. Finally, add 50µL stop solution to the wells and read at 450nm immediately. The binding activity of TNFRSF14 and TNFa was shown in Figure 1, and this effect was in a dose dependent manner.

Coud-Clone Corp.




Figure 1. The binding activity of TNFRSF14 with TNFa.

[IDENTIFICATION]




Figure 2. SDS-PAGE

Sample: Active recombinant TNFRSF14, Human

Cloud-Clone Corp.




Figure 3. Western Blot

Sample: Recombinant TNFRSF14, Human;

Antibody: Rabbit Anti-Human TNFRSF14 Ab (PAD926Hu01)

1304 Langham Creek Dr, Suite 226, Huustiin, TX 77084, USA | 001-888-960-7402 | www.cloud-cloue.us | mail/g cloud-clone.us Export Processing Zone, Wuhan, Hubei 430056, PRC | 0086-300-880-0687 | www.cloud-clone.com | mail/g cloud-clone.com